Department of Surgery, Tokyo Medical University, Shinjuku, Tokyo, Japan.
J Proteomics. 2010 Apr 18;73(6):1100-10. doi: 10.1016/j.jprot.2009.11.010. Epub 2009 Nov 24.
A preceding paper suggested 81 candidates of stage-specifically expressed proteins for either stage IA or IIIA by global shotgun proteomics and spectral counting. Six proteins, a subset of these proteins, were chosen for a further verification study since they are potentially soluble and/or secretory, which nature is convenient for detecting them in blood in clinical practice. The multiple-reaction monitoring (MRM) quantitative analysis suggested that napsin-A and anterior gradient protein 2 homolog (hAG-2) out of the 6 candidates would be useful for determining stage IA or IIIA and are related to metastasis. In the study we noted that stage IIIA patients with better outcome showed napsin-A profiles similar to that of stage IA patients. We therefore examined 14 additional patients for analysis, which contained the IA-stage patients of poorer outcome and the IIIA-stage patients of better outcome. The MRM analysis of napsin-A for all patients suggests that napsin-A contents correlate with better outcome in stage IA. This and discovery studies demonstrate that direct isolation of tumor cells alone by laser microdissection (LMD) greatly reduces complexity on comprehensive analyses, and that MRM mass spectrometry using the endogenous internal standard is a feasible technology for quantitative verification of target proteins in formalin-fixed paraffin embedded (FFPE) tissues.
前文通过全蛋白质组shotgun 分析和谱计数方法,提出了 81 个特定于分期的候选蛋白,用于分期 IA 或 IIIA。由于这 6 种蛋白具有潜在的可溶性和/或分泌性,这在性质上便于在临床实践中从血液中检测到,因此选择了其中的一部分进行进一步验证研究。多重反应监测(MRM)定量分析表明,这 6 种候选蛋白中的 napsin-A 和前梯度蛋白 2 同源物(hAG-2)可用于确定 IA 期或 IIIA 期,且与转移相关。在研究中我们注意到,预后较好的 IIIA 期患者的 napsin-A 图谱与 IA 期患者相似。因此,我们对另外 14 名患者进行了分析,其中包括预后较差的 IA 期患者和预后较好的 IIIA 期患者。对所有患者的 napsin-A 的 MRM 分析表明,IA 期患者的 napsin-A 含量与预后较好相关。这些研究和发现表明,通过激光显微切割(LMD)直接分离肿瘤细胞,大大降低了综合分析的复杂性,并且使用内源性内标进行 MRM 质谱分析是对福尔马林固定石蜡包埋(FFPE)组织中目标蛋白进行定量验证的可行技术。